Ophthalmoplegia Market Report 2026

Ophthalmoplegia Market Overview

• Ophthalmoplegia market size has reached to $1.84 billion in 2025 • Expected to grow to $2.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Increasing Incidence Of Neurological Disorders Driving The Growth Of The Market Due to Rising Diagnosis Rates And Advancements In Treatment Options • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ophthalmoplegia Market?

Ophthalmoplegia refers to the paralysis or weakness of one or more of the muscles that control eye movement. This condition can affect voluntary or involuntary eye movements and may be caused by neurological disorders, muscle diseases, or vascular conditions. The main types of ophthalmoplegia are external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia is the paralysis or weakness of extraocular muscles, causing impaired eye movement and drooping eyelids. It is treated with surgery or drug therapy and is used by end-users such as hospitals, clinics, and ambulatory care centers.

What Is The Ophthalmoplegia Market Growth Forecast?

The ophthalmoplegia market size is expected to see strong growth in the next few years. It will grow to $2.95 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in minimally invasive surgical techniques, growth of targeted pharmacological therapies, rising tele-ophthalmology adoption, increasing government initiatives for rare eye disorder management, growth in personalized medicine and genetic diagnostics. Major trends in the forecast period include increasing adoption of minimally invasive ophthalmoplegia surgeries, rising use of targeted drug therapies for eye muscle disorders, growing focus on early diagnosis and screening, expansion of tele-ophthalmology for patient monitoring, rising awareness about neurological and muscular eye conditions.

Global Ophthalmoplegia Market Segmentation

1) By Type: External Opthalmoplegia, Internuclear Opthalmoplegia 2) By Treatment: Surgery, Drug Treatment 3) By End-User: Hospitals, Clinics, Ambulatory Clinics Subsegments: 1) By External Ophthalmoplegia: Chronic Progressive External Ophthalmoplegia (CPEO), Myasthenic External Ophthalmoplegia, Mitochondrial Myopathy-Associated External Ophthalmoplegia 2) By Internuclear Ophthalmoplegia: Unilateral Internuclear Ophthalmoplegia, Bilateral Internuclear Ophthalmoplegia

What Are The Drivers Of The Ophthalmoplegia Market?

The increasing incidence of neurological disorders is expected to propel the growth of the ophthalmoplegia market going forward. Neurological disorders refer to medical conditions that affect the nervous system, including the brain, spinal cord, and nerves, leading to symptoms such as muscle weakness, coordination issues, and cognitive impairments. The increasing incidence of neurological disorders is due to genetic predisposition, which makes individuals more susceptible to conditions such as Alzheimer's and Parkinson's, and lifestyle changes such as poor diet, sedentary behavior, and chronic stress, which contribute to neurodegeneration and impaired brain function. Ophthalmoplegia helps diagnose neurological disorders such as Alzheimer's disease, multiple sclerosis, and stroke by indicating impaired eye muscle control, which reflects underlying nervous system dysfunction. For instance, in March 2023, according to the Alzheimer's Association, a US-based nonprofit voluntary health organization, in 2023, about 6.7 million Americans aged 65 and older are living with Alzheimer's dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the increasing incidence of neurological disorders is driving the growth of the ophthalmoplegia industry. The rising prevalence of autoimmune conditions is expected to propel the growth of the ophthalmoplegia market going forward. Autoimmune conditions refer to disorders in which the immune system mistakenly attacks the body's own healthy cells, leading to inflammation and tissue damage. The prevalence of autoimmune diseases is increasing, as certain genetic variants can lead to an overactive immune response, making individuals more susceptible to mistakenly attacking their own tissues. This genetic susceptibility, combined with environmental triggers such as infections, stress, and lifestyle factors, contributes to the rising incidence of autoimmune conditions. Ophthalmoplegia treatment, when associated with autoimmune conditions, helps identify underlying immune system dysfunctions, enabling targeted treatments that address both muscular paralysis and the root autoimmune disorder. For instance, in March 2023, according to the Society for Women’s Health Research, a U.S.-based non-profit organization, autoimmune diseases are estimated to affect 23.5 million to 50 million people. Globally, the rates of autoimmune diseases are rising by between 3 and 9 percent each year. Therefore, the rising prevalence of autoimmune conditions is driving the growth of the ophthalmoplegia industry. The increasing cases of head injuries or trauma are expected to propel the growth of the ophthalmoplegia market going forward. Head injuries or trauma refer to any damage to the scalp, skull, or brain caused by external force, such as a fall, accident, or impact. The increasing cases of head injuries or trauma are attributed to factors such as rising road accidents, as high-speed collisions, lack of helmet use, and reckless driving significantly increase the risk of severe head impacts. Additionally, workplace accidents, falls, sports-related injuries, and violence contribute to the growing incidence of traumatic brain injuries. Ophthalmoplegia helps assess head injuries or trauma by indicating potential neurological damage through impaired eye movement, allowing for early diagnosis and intervention. For instance, in 2023, according to the report published by the Wisconsin Department of Health Services, a US-based government agency, the number of traumatic injuries caused by assault increased by 3% in 2023 compared to 2022, rising from 1,544 cases in 2022 to 1,584 cases in 2023. Therefore, the increasing cases of head injuries or trauma are driving the growth of the ophthalmoplegia industry.

Key Players In The Global Ophthalmoplegia Market

Major companies operating in the ophthalmoplegia market are Hoffmann‑La Roche Ltd., AbbVie Inc., Novartis AG., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Bayer AG., Santen Pharmaceutical Co. Ltd., Oculis Holding AG., Clearside Biomedical Inc., ViGeneron GmbH, GenSight Biologics SA, EyeBio Inc., Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Eli Lilly and Company, Bristol‑Myers Squibb, Amgen Inc., Vertex Pharmaceuticals Inc., Acorda Therapeutics Inc., Biogen Inc., NicOx S.A.

Regional Outlook

North America was the largest region in the ophthalmoplegia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ophthalmoplegia Market?

The ophthalmoplegia market consists of revenues earned by entities by providing services such as diagnosis and imaging services, neurological and ophthalmic evaluations, genetic testing and counselling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The ophthalmoplegia market also includes sales of eye patches and prisms, neuromuscular electrical stimulation (NMES) devices, corticosteroids, immunosuppressants, and botulinum toxin injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ophthalmoplegia Market Report 2026?

The ophthalmoplegia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmoplegia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.